Journal article · 2026
Checkpoint inhibitor combinations: the trial-to-approval gap
Nature Reviews Drug Discovery · Published 4 November 2026 · DOI 10.1038/d41573-026-00174-7
In brief
“Checkpoint inhibitor combinations: the trial-to-approval gap” is a 2026 journal article by Fahad A. Benthani and 2 co-authors, published in Nature Reviews Drug Discovery. OpenAlex counts 0 citations as of 17 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 0
- Authors
- 3
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Benthani, F. A., Upadhaya, S., & Zhou, A. Y. (2026). Checkpoint inhibitor combinations: the trial-to-approval gap. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7
MLA 9
Benthani, Fahad A., et al. “Checkpoint inhibitor combinations: the trial-to-approval gap.” Nature Reviews Drug Discovery, 2026. https://doi.org/10.1038/d41573-026-00174-7.
Chicago
Benthani, Fahad A., Samik Upadhaya, and Alicia Yiran Zhou. 2026. “Checkpoint inhibitor combinations: the trial-to-approval gap.” Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7.
Harvard
Benthani, F. A., Upadhaya, S. and Zhou, A. Y. (2026) ‘Checkpoint inhibitor combinations: the trial-to-approval gap’, Nature Reviews Drug Discovery. doi:10.1038/d41573-026-00174-7.
IEEE
F. A. Benthani, S. Upadhaya, and A. Y. Zhou, “Checkpoint inhibitor combinations: the trial-to-approval gap,” Nature Reviews Drug Discovery, 2026, doi: 10.1038/d41573-026-00174-7.
BibTeX
@article{benthani2026checkpoint,
title = {{Checkpoint inhibitor combinations: the trial-to-approval gap}},
author = {Benthani, Fahad A. and Upadhaya, Samik and Zhou, Alicia Yiran},
journal = {Nature Reviews Drug Discovery},
year = {2026},
doi = {10.1038/d41573-026-00174-7},
url = {https://doi.org/10.1038/d41573-026-00174-7}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- immune checkpoint inhibitors
- combination therapy
- drug approval
- cancer immunotherapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Benthani, F. A., Upadhaya, S., & Zhou, A. Y. (2026). Checkpoint inhibitor combinations: the trial-to-approval gap. Nature Reviews Drug Discovery. https://doi.org/10.1038/d41573-026-00174-7
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Fahad A. Benthani, Samik Upadhaya, Alicia Yiran Zhou.
What is the DOI of this paper?
10.1038/d41573-026-00174-7, permanently at https://doi.org/10.1038/d41573-026-00174-7. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.